Press Releases Priveterra Acquisition Corp. II

Equities

PMGM

US8765451047

Delayed Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
11.05 ^USD	-0.36%		0.00%	+0.55%

May. 09	Priveterra Acquisition Corp. II(NasdaqCM:PMGM) dropped from NASDAQ Composite Index	CI
2023	Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AEON Biopharma Reports First Quarter 2024 Financial Results	May. 14	AQ
AEON Biopharma Provides Update on Development Pipeline	May. 09	AQ
Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K	May. 03	BU
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine	May. 03	AQ
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024	Apr. 01	AQ
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants	Mar. 30	AQ
AEON Biopharma Announces Redemption of Public Warrants	Mar. 29	AQ
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 29	AQ
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	Mar. 19	AQ
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements	Mar. 19	AQ
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference	Jan. 18	AQ
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	Dec. 12	AQ
AEON Biopharma Reports Third Quarter 2023 Financial Results	Nov. 13	AQ
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine	23-10-19	AQ
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®	23-08-29	AQ
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache	23-08-24	AQ
Tastemaker Acquisition : Announces Termination of Business Combination Agreement - Form 8-K	23-06-22	PU
TASTEMAKER ACQUISITION CORP. : Termination of a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits (form 8-K)	23-06-22	AQ
TASTEMAKER ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-30	AQ
Quality Gold, Inc. Announces Acquisition of HERCO Jewelry Company	23-01-19	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Priveterra Acquisition Corp. II

Equities

PMGM

US8765451047

Press Releases

Filters